Screening of asymptomatic left ventricular systolic dysfunction in cardiovascular high-risk patients. Pilot program experience based on the use of ECG and natriuretic peptides;Lo screening della disfunzione sistolica ventricolare sinistra asintomatica nei pazienti ad alto rischio cardiovascolare. Esperienza pilota di un programma basato sull'utilizzo dell'ECG e dei peptidi natriuretici

Giornale Italiano di Cardiologia

Volumn 9, Issue 12, 2008, Pages 835-843

  Tarantini, Luigi ^a   Cioffi, Giovanni ^b   Di Lenarda, Andrea ^c   Valle, Roberto ^d   Pulignano, Giovanni ^e   Del Sindaco, Donatella ^f   Frigo, Gianfranco ^a   Soravia, Giorgio ^a   Tessier, Renato ^a   Catania, Giuseppe ^a  

^a SAN MARTINO HOSPITAL   (Italy)

^b Villa Bianca Hospital   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d Ospedale Civile   (Italy)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f INRCA   (Italy)

Author keywords

Heart failure; Natriuretic peptides; Screening programs; Systolic dysfunction

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIAGNOSTIC AGENT; NATRIURETIC FACTOR;

ADULT; AGED; ALCOHOLISM; ARTICLE; BRONCHOPNEUMONIA; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHEMOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART BUNDLE BRANCH BLOCK; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; OBESITY; PROTEIN BLOOD LEVEL; Q WAVE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTOLIC DYSFUNCTION; VALVULAR HEART DISEASE; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; FEASIBILITY STUDY; FEMALE; HEALTH CARE QUALITY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; ELECTROCARDIOGRAPHY; FEASIBILITY STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PROGRAM EVALUATION; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 59449105413     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Kosiborod M, Lichtman JH, Heidenreich PA, et al. National trends in outcomes among elderly patients with heart failure. Am J Med 2006; 119: 616.e1-e7.
2. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J 2004; 25: 1614-9.
3. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001; 3: 283-91.
4. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More "malignant" than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3: 315-22.
5. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 2005; 46: e1-e82.
6. Heart Failure Society of America. Executive summary: HF-SA 2006 comprehensive heart failure practice guideline. J Card Fail 2006; 12: 10-38.
7. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med 1999; 159: 1197-204.
8. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161: 996-1002.
9. Chen YT, Vaccarino V, Williams CS, Butler J, Berkman LF, Krumholz HM. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999; 106: 605-12.
10. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000; 35: 1628-37.
11. Lewis EF, Moye LA, Rouleau JL, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 2003; 42: 1446-53.
12. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003; 108: 977-82.
13. Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare R; Midlands Research Practices Consortium (MidReC). Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5-year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007; 28: 1128-34.
14. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 2001; 88: 1298-300.
15. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a followup study. Lancet 2003; 361: 1843-8.
16. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
17. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-6.
18. McMurray JV, McDonagh TA, Davie AP, Cleland JG, Francis CM, Morrison C. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J 1998; 19: 842-6.
19. Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006; 113: 2851-60.
20. Arnold JM, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007; 23: 21-45.
21. Consensus Conference. Il percorso assistenziale del paziente con scompenso cardiaco. G Ital Cardiol 2006; 7: 383-432.
22. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002; 288: 1252-9.
23. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-9.
24. Hedberg P, Lonnberg I, Jonason T, Nilsson G, Pehrsson K, Ringqvist I. Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women. Am Heart J 2004; 148: 524-9.
25. Okin PM, Devereux RB, Nieminen MS, et al, for the LIFE Study Investigators. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Circulation 2006; 113: 67-73.
26. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-67.
27. Davis RC, Hobbs FDR, Kenkre JR, et al. Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ 2002; 325: 1156-60.
28. Colucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007; 116: 49-56.
29. Fischer M, Baessler A, Holmer SR, et al. Epidemiology of left ventricular systolic dysfunction in the general population of Germany: results of an echocardiographic study of a large population-based sample. Z Kardiol 2003; 92: 294-302.
30. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41: 113-20.
31. Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004; 43: 1019-26.
32. Schocken DD, Benjamin EJ, Fonarow GC, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117: 2544-65.
33. Galasko GI, Barnes SC, Collinson P, Lahiri A, Senior R. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? Eur Heart J 2006; 27: 193-200.
34. Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996; 312: 222.
35. Christian TF, Miller TD, Chareonthaitawee P, Hodge DO, O'Connor MK, Gibbons RJ. Prevalence of normal resting left ventricular function with normal rest electrocardiograms. Am J Cardiol 1997; 79: 1295-8.
36. Mosterd A, de Bruijne MC, Hoes AW, Deckers JW, Hofman A, Grobbee DE. Usefulness of echocardiography in detecting left ventricular dysfunction in population-based studies (the Rotterdam study). Am J Cardiol 1997; 79: 103-4.
37. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
38. Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20: 1799-807.
39. McDonagh TA, Cunningham AD, Morrison CE, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86: 21-6.
40. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-63.
41. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-16.
42. Choure A, Tang WH, Mills RM. Natriuretic peptides in valvular heart diseases. Heart Fail Clin 2006; 2: 345-52.